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Summary CEA was extracted by the perchloric acid method from primary adenocarcinomas of the colon
and the ovary, from ascitic and pleural fluids from patients with pancreatic, lung and breast cancer, and from
the cyst fluid of a benign ovarian cystadenoma. Further purification included gel filtration and affinity
chromatography. Antisera against CEA from colon, breast, ovary, lung and pancreatic cancer were produced
in rabbits. In double diffusion experiments, all these CEA samples showed a reaction of complete
immunological identity with all the anti-CEA sera, whatever their origin. CEA from colon, breast, pancreas
and ovary were labelled with 1251 and used in radioimmunological experiments. In a radioimmunological
system where the tracer and the antiserum were constant, all the CEA used as standards gave parallel
inhibition curves, having nearly identical slopes. This was another criterion of immunological identity. Sera of
numerous cancer patients were assayed in several RIA systems, one of them being the classical system with
colonic CEA as tracer and anti-colonic CEA as antiserum, the others being "organ specific" systems. The
values obtained in these assays were found to be highly correlated: the rank coefficient of correlation between
colonic and breast cancer RIA systems was rs=0.96, that between colonic and ovarian RIA systems, 0.92, that
between colonic and pancreatic RIA systems, 0.97 and that between colonic and lung RIA systems 0.96. It is
thus concluded that by use of different organ-derived CEA preparations and their corresponding polyclonal
antisera, no significative differences in serum CEA levels may be expected. No evidence of organ specificity of
serum CEA was found.
The carcinoembryonic antigen of the digestive
system (CEA) was first described by Gold &
Freedman (1965) as a tumour- and organ-specific
antigen, as it was found only in the digestive
adenocarcinomas. Later studies modified these
conclusions, since CEA was found in the extracts of
various non-digestive carcinomas (breast, lung,
ovary, etc.) and of non-cancerous tissues
(Pusztaszeri & Mach, 1973), especially of normal
colonic mucosa. As for the latter, it was shown to
be identical, biochemically and immunochemically,
to the CEA extracted from colonic tumours
(Fritsche & Mach, 1977; Egan et al., 1977). A
similar comparison between CEA extracted from
non-digestive tumours and that of the colon would
be very useful; better results might be expected
when assaying CEA in sera of patients with non-
digestive cancers by using CEA obtained from non-
digestive organs and antisera prepared against these
CEA. Such studies have not been conducted before,
except by Santen et al. (1980) who prepared an
antiserum to breast CEA. We report here the results
of a study where we first prepared CEA from
tumours of the ovary, breast, lung, pancreas and
Correspondence: R. Lamerz.
Received 23 November 1982, accepted 22 March 1983.
colon, followed by antisera against each of them.
With these reagents, the problem of CEA organ
specificity was investigated.
Materials and methods
Tumours/CEA source
Surgical tumour specimens of primary colon cancer
(n=110) and primary ovarian cancer (n=10) - both
of the adenocarcinoma type - as well as ascitic and
pleural fluids from patients with breast cancer
(n= 3), lung cancer (n= 1), pancreatic cancer (n=1),
and a cyst fluid of a patient with benign ovarian
cystadenoma were used for CEA extraction.
Serum specimens
Serum samples of patients with breast cancer (207),
ovarian cancer (42), pancreatic cancer (10), lung
cancer (27), gastrointestinal cancer (70; 26 gastric, 44
colorectal), and with metastatic disease of unknown
primary origin (11) were investigated.
CEA preparation
(a) Extraction. Pooled tumour and single body
fluid specimens were extracted by perchloric824 R. LAMERZ & P. BURTIN
acfd after the method of Krupey et al. (1972). In
brief, thawed cryopreserved tumour specimens
were dissected with scissors, transferred to a
multimix machine and homogenised in saline in
a Virtis Homogenizer and Potter-Elvehjeun
apparatus. The tumour homogenate and body
fluid specimens were then extracted in an equal
volume of 1.2 M perchloric acid (PCA) and
centrifuged. Within 45 min after the initiation of
PCA extraction, the supernatant was dialysed
against tap then distilled water without prior
neutralisation and thereafter concentrated,
ultra-filtered and lyophilised.
(b) Purification of CEA. Crude PCA extract (150-
250mg) was chromatographed by gel-filtration
on Sephadex 6B (2.5 x 80cm column; 0.05 M
Tris-HCI buffer+0.1 N NaCI, pH 6.0) to yield 4
fractions. The CEA-positive fraction(s) II and/or
III detected by immunodiffusion and RIA were
further separated on Sephadex G200 column
(2.5 x 80cm) to yield 3 peaks. The CEA-positive
fraction I was purified by immunoadsorption
on CNBr-activated Sepharose4B column
(2.0 x 20cm) with coupled rabbit anti-CEA IgG
(washing buffer: 0.15M NaCI+0.02M Na-
phosphate=PBS, pH 7.3; eluting buffer: PBS
+2.0 M KSCN). Further purification of the
CEA-containing fraction was achieved by
immunoadsorption on CNBr-activated
Sepharose 4B coupled with rabbit anti-human
serum IgG, where the non-adsorbed fraction
was used. The purity of CEA fractions was
checked by double immunodiffusion with
antisera (polyvalent and monospecific) against
contaminating serum and tissue proteins (see
below) including anti-NCA-serum, as well as by
RIA with anti-NCA-serum.
Antisera
Female rabbits (New Zealand White) were
immunised with purified CEA preparations (or
normal human serum proteins) following the
modified method of Hijmans et al. (1969) by two s.c.
injections, each of 100-200 ug CEA (one week
apart; the first one with Freund's complete adjuvant
and the second with incomplete adjuvant) and 3
weeks later by 6 i.v. booster injections (2 p'er week
with increasing volumes of 0.05, 0.1, 0.1, 0.2, 0.2 up
to 0.4ml from a total of 500 ug in 2 ml of alum
hydroxide-precipitated CEA). Animals were
sacrificed 2-3 months after the commencement of
immunisation and the antisera absorbed by normal
human serum (lyophilised, 10-30mgmlP
antiserum), ABO red blood cells and by normal
lung PCA extract (10-20mgml-1). Antisera used
for immunoadsorption and part of the antisera used
for radioimmunoassay were finally purified by
gradient elution on DEAE-Sephacel (buffer: 0.01 M
Na-phosphate pH 8.0/0.5 M Na-phosphate, pH 4.5);
only the IgG fractions were used.
For analytical purposes, two reference anti-
colonic CEA antisera (one given by Dr. Hirata,
Abbott Lab., the other from LKB), an anti-NCA-
serum (No. 43), an antiserum against normal colon
PCA extract and several commercial antisera
against serum and tissue proteins (polyvalent: anti-
human serum proteins; monospecific: anti-albumin,
anti-acid alpha1-globulin, anti-haptoglobin, anti-
transferrin, anti-alpha1-chymotrypsin, anti-ferritin,
anti-lactoferrin, each of Behringwerke AG) were
used.
CEA-analysis
Crude extracts and CEA preparations as well as of
the anti-CEA-antisera were analyzed by
Ouchterlony double immunodiffusion on
microslides and by immunoelectrophoresis.
CEA-radioimmunoassay
CEA preparations used as tracer were labelled by
the Chloramine T method (Hunter & Greenwood,
1962). Briefly, 5-15,pg of CEA were labelled with
300 uCi Na125I (Hoechst AG) for 30-45 min at
room temperature. The tracer was separated from
free iodine on Sephadex G50 fine (1 x 15 cm column)
and further purified on Sephadex G200 (1.5 x 35 cm
column). After establishing the relationship between
immunoreactive antigen and antibody in dilution
curves, the tracer was diluted to a working dilution
and stored frozen in 10ml portions until use.
The RIA was developed as double antibody test:
the first antibody was anti-CEA IgG from the
rabbit and the second an anti-rabbit-IgG-antiserum
from a goat. For direct serum determinations,
aliquots of CEA-free serum were added to standard
dilutions (2.5-160ngml-).
Statistical analysis
Statistical comparison of the regression coefficients
of the different standard inhibition curves and the
Spearman's rank coefficient of correlation of serum
CEA determinations by different CEA
radioimmunoassay systems were computed by
conventional methods (Sachs, 1972).
Results
CEA preparations and antisera
CEA preparations and antisera are summarised in
Table I. As shown in Figure 1, the different CEACOMPARISON OF CEAs FROM DIFFERENT ORGANS 825
Table 1 Antigens and antisera used in Ouchterlony and
RIA experiments
Antigens Antisera
Colonic cancer CEA Anti-colonic cancer CEA
CEA-CO A-CEA-CO
Ouchterlony: LKB
RIA: Xaver IGG
Breast cancer CEA Anti-breast cancer CEA
CEA-MT A-CEA-MT No. 18
Ovarian cancer CEA Anti-ovarian cancer CEA
CEA-OV A-CEA-OV No. 495
Pancreatic cancer CEA Anti-pancreatic cancer CEA
CEA-PA A-CEA-PA No. 30
Lung cancer CEA Anti-lung cancer CEA
CEA-BC A-CEA-BC No. 32
preparations - colonic, pancreatic, breast, ovarian
and lung cancer CEA - give an immunological
reaction of complete identity in double diffusion
experiments - even by the use of different anti-
CEA-antisera (A-CEA-CO, A-CEA-MT, A-CEA-
OV, A-CEA-PA, A-CEA-BC). There is no spur of
one over another CEA precipitin line using different
antisera. In contrast, the slight doubling of some of
the precipitin lines may be explained by an
imbalance of the immunological reaction caused by
the different concentrations of antigens and
antibodies. When the different CEA preparations
were tested against a monospecific anti-NCA serum,
no precipitin lines were observed. In addition,
absorption of the different anti-CEA-antisera
specimens by CEA aliquots of different origins (0.1-
0.4 mgml-1 antiserum) resulted in a complete
disappearance of the precipitin lines.
CEA labelling
As the reference CEA we used our colonic CEA
preparation of the CEA radioimmunoassay
developed since 1975 (Lamerz & Ruider, 1976).
During that period, more than 40 regular labelling
experiments of colonic CEA have been carried out.
Generally, the protein peak of the first column
(Sephadex G50 fine) contained between 17.4 and
78.2% of radioactivity. Thirty-five-65% of the peak
obtained by the second column (Sephadex G200)
were used as tracer and yielded a specific activity
between 6.7 and 12.5 1Ci Mg 1. It is noteworthy
that only the high mol. wt. peak fraction of the
second column turned out to be immunoreactive,
the residual part containing inactivated material
because of the chloramine T and/or iodination
procedures. In this respect, results were comparable
for CEA prepared from cancers of the breast, ovary,
pancreas and lung, which had a specific activity of
9.4, 6.5, 6.9 and 15.4pCi ug -I respectively.
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Figure 1 Comparative reactivity in agar gels of CEA
preparations of various origins and anti-CEA sera. (a)
Comparison of CEA preparations from tumours of 5
different locations (CO, MT, BC, PA and OV) with
antisera against CEA-CO and CEA-OV. Complete
identity was obtained. (b) Comparison of CEA
preparations from tumours of 5 different locations
(CO, MT, BC, PA and OV) with antisera against
CEA-PA and CEA-MT. (c) Comparative reactivity of
CEA preparations from tumours of 4 different
locations (CO, PA, OV and MT) with 5 different anti-
CEA sera (A-CO, A-MT, A-OV, A-PA and A-BC).
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Antibody dilution curves
All the anti-CEA sera were used to bind labelled
CEAs of different origins. The binding capacity and
the slope of the dilution curves were nearly the
same when a given tracer was studied with different
antisera: this is shown in Figure 2 where the
binding of CEA-PA by antisera against CEA-CO,
CEA-OV, CEA-MT and CEA-PA in comparison to
an anti-NCA-serum is depicted. Similar results were
obtained with other tracers. The antibody titre
varied from one antiserum to another (50% end
point of antibody dilution between 1/120,000 for
A-CEA-CO, 1/15,000 for A-CEA-PA, A-CEA-MT,
A-CEA-BC and 1/7,000 for A-CEA-OV).
Standard inhibition curves
The results of many experiments can be
summarized as follows:
(1) Within one RIA system where the tracer and
the first antibody were the same, different
inhibitors, i.e. CEA identical 'to the tracer or
originating from other organs, gave parallel
inhibition curves: the slopes of these curves were
the same. Figures 3 and 4 show some of the
inhibition curves obtained when 2 standards
(CEA from pancreas and colon) were compared
in one RIA system. Other experiments gave
similar results.
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(2) When the same tracer was tested with 2
different antisera, one of them specific for the
CEA originating from the same organ as the
tracer, and the other prepared with a CEA of
different origin, inhibition curves were obtained
in each case with the 2 CEA standards
corresponding to the antisera. The slopes of
these curves, i.e. the B values of the logit-log
regression lines reported in Table II were
roughly identical (Expts. 1-4, 13-16, 29-32; N.S.
- P<0.05), moderately different (Expts. 5-8,
9-12, 17-20; P<10-2), or significantly different
(Expts. 21-24, 25-28; P<10-3). It is worth
mentioning that the slope of the inhibition
curves varied from 2.10 to 2.51, i.e. in a
significant manner, when different preparations
of CEA-CO were used as tracer.
(3) When different tracers were compared with the
same antiserum, the slopes of the inhibition
curves given by the same CEA sample were
different. For instance, the anti-CEA-CO IgG
was reacted with CEA samples prepared from
various organs. The B values varied from 2.51
to 3.19 when CEA-PA and CEA-MT were
respectively used as tracers, and CEA-CO as
inhibitor. The differences were especially
marked when anti-CEA-OV was used with
CEA-CO and CEA-OV as tracers and
standards: the B values were 2.02-2.01 with
CEA-CO as tracer, and 2.83-2.92 with CEA-OV
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Figure 2 Antibody dilution curves of 4 different anti-CEA-antisera (A-CEA-CO, A-CEA-OV, A-CEA-MT
and A-CEA-PA) and an anti-NCA-antiserum by use of a pancreatic cancer CEA tracer (CEA-PA* 10/80).
Ordinate: bound activity (B) as per cent oftotal activity (T) after subtraction ofnon-specific binding (N) (=2%).
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Figure 3 CEA standard inhibition lines (logit-log plot) by use of one tracer (colonic cancer CEA), two
antisera (above: anti-colonic CEA antiserum; below: anti-pancreatic CEA antiserum) and two standards
(standard CEA-CO and CEA-PA). Ordinate: bound activity (B) as per cent of maximal binding (BO) without
inhibition and after subtraction of non-specific binding (N).
as tracer (Table II, expts. 3-4 and 7-8); and
when anti-CEA-BC was reacted with CEA-CO
and CEA-BC (B values 1.70-1.71 and 2.68-2.71
respectively as shown in Table II, expts. 27-28
and 31-32). In every case, CEA-CO gave lower
B values than all the other CEAs.
All these data lead to the conclusion that the
CEAs of different origins have the same inhibiting
capacity, i.e. are antigenically identical. However,
the labelling procedure might alter their reactivity
in a manner which differs from one sanmple to
another. It does not appear that the organ origin of
CEA samples makes them more or less sensitive to
this alteration, as colonic CEA itself gave variable
results following iodination. Hence heterogeneity of
the tracers plays a major role in the difference
*between inhibition curves. Finally, there is certainly
some heterogeneity among the antisera which could
also influence the variations between curves.
E
Serum CEA determinations
Sera of patients with gastrointestinal, breast,
pancreas, ovary and lung cancer, or cancer of
unknown primary origin were assayed for CEA
content in different RIA systems: they were used to
inhibit the binding of radiolabelled CEAs (of
various origins) to their respective antisera. Figures
5 and 6 show that whatever the antiserum and the
tracer, the CEA values were highly correlated. The
rank coefficients of correlation were rs=0.992
(P< 10-3; n=91) when the ovarian and colonic
RIA systems were compared, and rs=0.979
(P< 10-3; n= 126) when the pancreatic and the
colonic RIA systems were studied in parallel. The rs
values were 0.978 (P< 10-3; n= 117) for the
comparison between breast and colonic RIA
systems, and 0.969 (P<10-3; n=119) for the
comparison between the lung and colonic RIA
systems (Figures 5 and 6).
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Table II Parameters of standard inhibition curves dependent on different tracers, antisera
and standards
Y=A+B*X
Stand. 50% point
Antiserum- +NHS ngml-1 A B Expt.
Tracer concentration inhib. (x+s) (x+s) (x+s) No.
CEA-CO
4/75-
7/80
(n=33)
A-CEA-CO (Xav) CEA-CO
1/80,000-
1/120,000
CEA-CO A-CEA-CO (Xav) CEA-CO
3/80 1/140,000 CEA-OV
A-CEA-OV (495) CEA-CO
1/10,000 CEA-OV
CEA-OV A-CEA-CO (Xav) CEA-CO
3/80 1/50,000 CEA-OV
A-CEA-OV (495) CEA-CO
1/3,000 CEA-OV
CEA-CO A-CEA-CO (Xav) CEA-CO
10/80 1/100,000 CEA-PA
A-CEA-PA (30) CEA-CO
1/25,000 CEA-PA
CEA-PA A-CEA-CO (Xav) CEA-CO
1/100,000 CEA-PA
A-CEA-PA (30) CEA-CO
1/10,000 CEA-PA
CEA-CO A-CEA-CO (Xav) CEA-CO
2/82 1/120,000 CEA-MT
A-CEA-MT (18) CEA-CO
1/12,000 CEA-MT
CEA-MT A-CEA-CO (Xav) CEA-CO
2/82 1/50,000 CEA-MT
A-CEA-MT (18) CEA-CO
1/8,000 CEA-MT
CEA-CO A-CEA-CO (Xav) CEA-CO
2/82 1/120,000 CEA-BC
A-CEA-BC (32) CEA-CO
1/12,000 CEA-BC
CEA-BC A-CEA-CO (Xav) CEA-CO
2/82 1/30,000 CEA-BC
A-CEA-BC (32) CEA-CO
1/12,000 CEA-BC
It is thus clear that when the serum of a non-
digestive cancer (breast, lung, ovary) was assayed in
(i) the conventional RIA, performed with colonic
CEA as tracer and standard and anti-colonic CEA
serum and (ii) "organ specific RIA", made with the
CEA extracted from the same organ as that afflicted
by the patient's cancer and the corresponding
antiserum the CEA values thus obtained were the
same or nearly identical in almost all cases.
Discussion
It is clear that our results do not support the
hypothesis of an organ specificity of CEA. All the
CEA samples gave reactions of identity in
Ouchterlony plates when reacted in criss-cross
experiments with antisera against these CEA
samples. Furthermore, the inhibition curves given
by these CEAs were parallel: this is strong evidence
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Figure 4 CEA standard inhibition lines (logit-log plot) by use of one tracer (pancreatic cancer CEA), two
antisera (above: anti-colonic CEA antiserum; below: anti-pancreatic CEA antiserum) and two standards
(standard CEA-CO and CEA-PA). Ordinate and abscissa as Figure 3.
for the absence of any antigenic difference between
them. Our conclusion is in agreement with the data
obtained by De Young & Ashman (1978). These
authors purified CEA from hepatic metastases of
tumours originating in colonic, stomach, lung,
pancreas and obtained also semipurified
preparations from other metastases, derived from
tumours of the breast, pancreas and oesophagus. In
all these preparations, CEA had a mol. wt in the
range of 200-300Kdaltons and a similar amino-
acid composition. The purified preparations did not
contain NCA. All of them were used in comparative
radioimmunoassays and gave parallel inhibition
curves, thus showing no immunological difference.
However, De Young & Ashman (1978) used only an
antiserum prepared against colonic CEA in their
comparative studies. They did not produce antisera
against CEA from non-colonic tumours; therefore,
they did not prove definitively that CEAs from
different organs are immunologically identical.
More recently Hill et al. (1981) described the
purification of a CEA sample from ascitic fluid of a
serous cystadenocarcinoma of the ovary. This
ovarian CEA gave a reaction of identity with a
colonic CEA in agar immunodiffusion, but here
again, only an antiserum against colonic CEA was
used. No antiserum against the isolated ovarian
carcinoma CEA was prepared. Comparison between
ovarian and colonic CEA was sought with one
antiserum only, thus allowing no definitive
conclusions.
Contrary data were reported by Santen et al.
(1980) who claimed to demonstrate an antigenic
difference between breast and colonic CEA, on the
grounds that in radio rocket experiments made with
anti-breast tumour extract serum, breast CEA serial
dilutions "gave greater changes in rocket heights
than did purified colon CEA". However, their
conclusions can be criticised because they did not
take into account the possible presence of NCA in
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Figure 5 Serum CEA levels of patients with various malignancies. Correlation between CEA values
determined by a reference colonic cancer CEA RIA system and an ovarian cancer CEA RIA system (above)
and a pancreatic cancer CEA RIA system (below).
their rather crude preparations, nor that of
antibodies cross-reacting with NCA in their anti-
breast CEA serum. Thus, they could have measured
both NCA and CEA in their radio rocket
immunoelectrophoresis experiments.
As a whole we conclude that all the evidence is
against organospecificity of CEA. Thus the assay of
CEA in sera of patients with non-digestive
carcinoma can be performed with a colonic CEA as
tracer and an anti-colonic CEA serum as antibody
source, as well as with reagents prepared with non-
digestive CEAs: the results are the same in our
experiments.
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Figure 6 Serum CEA levels of patients with various malignancies. Correlation between CEA values
determined by a reference colonic cancer CEA RIA system and a breast cancer CEA RIA system (above) and
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